Durability score
35/100
Valuation score
29.8/100
Momentum score
33.6/100
Market Capitalizati...
34038.3
AVG Broker Target
798.4
PE TTM Price to Ear...
14.1
Aurobindo Pharma Ltd.    
17 Jul 2018
580.95
2.31%
Business Line
Europe now blips prominently on the radar of some Indian pharma companies. A case in point is the latest acquisition of Canadian drug-maker Apotex's
Aurobindo Pharma Ltd. is trading below it's 30 day SMA of 601.97
Aurobindo Pharma Ltd.    
17 Jul 2018
580.95
2.31%
Business Standard
Unlikely to add to profits in first 2 years; working capital may rise
Promoters pledge increased to 51.87% of holdings in Jun 2018 qtr.
Aurobindo Pharma Ltd.    
16 Jul 2018
580.95
2.31%
Business Line
Shares of Aurobindo Pharma dropped as much as 5.6 per cent to Rs 569.10 on the BSE.After opening the session higher at Rs Rs 610 against the previous
Aurobindo Pharma Ltd.    
14 Jul 2018
580.95
2.31%
Business Line
The Hyderabad-based Aurobindo Pharma Ltd has entered into a definite agreement with global generics maker Apotex to acquire its business in Poland,
Aurobindo Pharma Ltd.    
14 Jul 2018
580.95
2.31%
Aurobindo Pharma Ltd.    
11 Jul 2018
580.95
2.31%
Business Standard
Street cautious as Mallinckrodt biz is declining amid enhanced scrutiny on opioid drugs
Aurobindo Pharma Ltd.    
11 Jul 2018
580.95
2.31%
default
Aurobindo Pharma Ltd.    
11 Jul 2018
580.95
2.31%
Aurobindo Pharma Ltd.    
10 Jul 2018
580.95
2.31%
Statement Of Investor Complaints For The Quarter Ended June 2018
BSE India
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- B.ADI REDDYDesignation :- Company Secretary and Compliance Officer
Aurobindo Pharma Ltd.    
10 Jul 2018
580.95
2.31%
Statement Of Investor Complaints For The Quarter Ended June 2018
BSE India
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- B.ADI REDDYDesignation :- Company Secretary and Compliance Officer
default
  • Stock Price (574.95) crossed below 30 Day SMA (597.1) on 16 July, 2018
  • Stock Price (574.95) crossed below 50 Day SMA (593.85) on 16 July, 2018
  • Stock Price (574.95) crossed below 100 Day SMA (596.78) on 16 July, 2018
  • Stock Price (606.95) crossed below 150 Day SMA (616.23) on 11 July, 2018
  • Way2Wealth released a Daily Note report for Aurobindo Pharma Ltd. on 03 Jul, 2018.
More triggered alerts
Ex-Date Dividend Amount Dividend Type Record Date
Feb. 20, 20181.00INTERIM-
Nov. 21, 20171.50INTERIM-
June 8, 20171.25INTERIM-
Nov. 24, 20161.25INTERIM-
June 9, 20160.70INTERIM-
All dividends by AUROPHARMA
Ex-Date Dividend Bonus Ratio Record Date
July 20, 20151:1July 21, 2015
All bonuses by AUROPHARMA
Ex-Date Dividend Old FVNew FV Record Date
Feb. 10, 201151Feb. 11, 2011
All splits by AUROPHARMA